These are top 10 stocks traded on the Robinhood UK platform in July
On Tuesday, UBS analyst team revised the price target for Aurobindo Pharma (NSE:ARBN) (ARBP:IN) shares, reducing it to INR 1,200 from a previous INR 1,333. Despite the adjustment, the firm maintained a Sell rating on the stock. The analysts cited Aurobindo Pharma’s forecast for high single-digit revenue growth, excluding gRevlimid, which is below the consensus expectation of 12% growth for the fiscal year 2026, excluding gRevlimid. Additionally, the company’s projected EBITDA margins of 21% fall short of the consensus estimate of 22%.
The revised financial expectations suggest a potential 7% reduction in EBITDA and a 9% decrease in earnings per share (EPS) compared to the consensus figures for FY26. The downgrade in guidance is primarily attributed to operational factors, including the Penicillin G new plant, which is expected to be operational for only 6-8 months in FY26. The company is also facing price erosion at gRevlimid and anticipates a flat performance at Eugia III.
Despite the subdued guidance for some segments, Aurobindo Pharma’s European operations continue to show strength. The company has projected an 8% revenue increase in the EU market, supported by six high-value launches associated with the loss of exclusivity.
The UBS analyst team’s report highlights the mixed performance across Aurobindo Pharma’s portfolio, with specific challenges in the company’s product lines and operations, tempered by positive developments in the European market. This nuanced view underpins the decision to adjust the price target while retaining the Sell rating on the company’s shares.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.